Skip to main content

Estrategias novedosas de ingeniería avanzada para optimizar la función y la persistencia de las células CAR-T en el mieloma múltiple

PI22/00647

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de I+D+i en Salud
Call year 2022
State Plan 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre INSTITUTO DE INVESTIGACIONES BIOMEDICAS AUGUST PI I SUNYER (IDIBAPS)
Execution centre INSTITUTO DE INVESTIGACIONES BIOMEDICAS AUGUST PI I SUNYER (IDIBAPS)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

PVR (CD155) epigenetic status mediates immunotherapy response in multiple myeloma

  • Martinez-Verbo, Laura
  • Veselinova, Yoana|||0000-0003-4124-9788
  • Llinàs-Arias, Pere|||0000-0002-3666-0532
  • García-Prieto, Carlos A.|||0000-0001-5021-6916
  • Noguera Castells, Aleix|||0000-0001-7436-6513
  • Pato, Miguel L.|||0000-0001-8840-7259
  • Bueno-Costa, Alberto|||0000-0001-8700-2540
  • Campillo-Marcos, Ignacio|||0000-0002-7657-7127
  • Villanueva, Lorea|||0000-0003-1858-7076
  • Oliver-Caldés, Aina|||0000-0002-7921-5420
  • Cardus, Oriol|||0000-0002-5446-5423
  • Salsench, Sergi V.|||0000-0002-4390-6887
  • García-Ortiz, Almudena
  • Valeri, Antonio
  • Rojas, Elizabeta A.
  • Barrena, Naroa|||0000-0003-4324-3371
  • Gutiérrez, Norma C.
  • Prósper, Felipe
  • Agirre, Xabier|||0000-0002-6558-9560
  • Fernández de Larrea, Carlos|||0000-0003-4930-9255
  • Martínez-López, Joaquín|||0000-0001-7908-0063
  • Ferrer, Gerardo|||0000-0002-4084-6815
  • Esteller, M|||0000-0003-4490-6093
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Clinical impact of [18F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myeloma

  • Zugasti, Inés
  • Tormo-Ratera, Marta
  • Oliver-Caldés, Aina
  • Soler-Perromat, Juan Carlos
  • González-Calle, Verónica
  • Moreno, David F.
  • Cabañas, Valentín
  • López-Muñoz, Nieves
  • Bartolomé-Solanas, Álvaro
  • Español-Rego, Marta
  • Reguera-Ortega, Juan Luis
  • Rosiñol, Laura
  • López-Corral, Lucía
  • Tovar, Natalia
  • Rodríguez-Lobato, Luis Gerardo
  • Álvarez-Pérez, Rosa María
  • Varea, Sara
  • Olesti, Eulalia
  • Gómez-Grande, Adolfo
  • Frutos, Laura
  • Tamayo, Pilar
  • Juan, Manel
  • Moraleda, José María
  • Urbano-Ispizúa, Álvaro
  • González-Navarro, Azucena
  • Martínez-López, Joaquín
  • Mateos, Maria Victoria
  • Tomás, Xavier
  • Setoain, Xavier
  • Fernández de Larrea, Carlos
Multiple myeloma (MM) remains incurable, with poor outcomes in heavily pretreated patients. Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising treatment; however, outcomes after such therapy in patients with soft-tissue plasmacytomas and other bone lesions remain poorly understood. This study included 63 patients with relapsed/refractory MM treated either in the CARTBCMA-HCB-01 clinical trial (ARI0002h; academic B-cell maturation antigen [BCMA]-targeted CAR T-cell therapy) or in compassionate use. The aim was to evaluate the impact of soft-tissue involvement (extramedullary [EMD] and paraskeletal [PS] plasmacytomas) in response, survival and safety. Baseline [18F]fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) from 5 participating centers were reviewed centrally. Of 63 patients, 52.4% presented plasmacytomas at the time of inclusion (21 PS, exclusively; and 12 EMD). Per responses, there were no significant differences between patients with and without plasmacytomas. A correlation was present between International Myeloma Working Group responses and those obtained by [18F]FDG-PET/CT at day 100 (Bologna criteria). No differences were observed in progression-free survival (PFS) or overall survival (OS) between patients with or without plasmacytomas. However, both PFS and OS were significantly shorter in patients with EMD. Interestingly, [18F]FDG-PET/CT response assessed on day 100, in accordance with the Bologna criteria, was predictive of survival outcomes. A metabolic tumor volume of ≥25 cm3 at baseline [18F]FDG-PET/CT was associated with earlier disease progression and shorter OS. These results highlight the importance of EMD evaluation by [18F]FDG-PET/CT before and after CAR T-cell infusion. This trial was registered at www.ClinicalTrials.gov as #NCT04309981; and EudraCT, 2019-001472-11., This study was supported by grants from the Instituto de Salud Carlos III (cofounded by the European Union) and the Spanish Ministry of Health (ICI19/00025 and PI22/00647), the RICORS-TERAV network (RD21/0017/0009 and RD21/0017/0019, RD21/0017/0001, RD21/0017/0006 and RD21/0017/0030), Red de Terapia Celular TERCEL (RD16/0011/0005), Fondo Europeo de Desarrollo Regional, 2021-SGR-01292 (AGAUR; Generalitat de Catalunya), Centro de Investigación Biomédica en Red de Cáncer (CB16/12/00369 and CB16/12/00489), La Caixa Foundation (CP042702/LCF/PR/GN18/50310007), Asociación Española Contra el Cancer LABAE21971FERN, and Fundació Bosch I Aymerich support. A.O.-C. from the resident grant Ajut Clínic-La Pedrera 2019, granted by Hospital Clínic de Barcelona. L.G.R.-L. has received funding from the CRIS Cancer Foundation (project number: PR_TMT_2023-6)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma

  • Uribe-Herranz, Mireia
  • Oliver-Caldés, Aina
  • Martínez-Micaelo, Neus
  • Español-Rego, Marta
  • Val-Casals, Maria
  • Martínez-Soler, Roberto
  • Rubio-Garcia, Elisa
  • Brunello, Valeria
  • Mihelic, Erik Z.
  • Klein-González, Nela
  • Benítez-Ribas, Daniel
  • Amigó, Núria
  • Vergara, Andrea
  • Ortiz-Maldonado, Valentín
  • Rodríguez-Lobato, Luis Gerardo
  • Delgado, Julio
  • Ortiz de Landazuri, Iñaki
  • González-Calle, Verónica
  • Cabañas, Valentín
  • Martín-Antonio, Beatriz
  • Pérez-Amill, Lorena
  • Reguera-Ortega, Juan Luis
  • Rodríguez-Otero, Paula
  • Paiva, Bruno
  • Martínez-López, Joaquín
  • Mateos, Maria Victoria
  • Pascal, Mariona
  • Urbano-Ispizúa, Álvaro
  • González-Navarro, Europa Azucena
  • Fernández de Larrea, Carlos
  • Juan, Manel
Multiple myeloma remains incurable despite advances in immunotherapies like chimeric antigen receptor (CAR) T-cell therapy. This study investigates the role of metabolites and gut microbiota in clinical outcomes in patients treated with the humanized B-cell maturation antigen (BCMA)-directed CAR-T therapy ARI0002h. Stool metabolites, particularly succinate, were associated with CAR T-cell phenotypes and persistence in patients. In CAR T-cell culture, succinate supplementation enhanced CD4+ central memory phenotype and respiratory capacity. In a murine myeloma model, a succinate-enhancing diet significantly improved CAR T-cell persistence and showed a trend toward better tumor control. Furthermore, Acidaminococcaceae, Monoglobaceae, or Akkermansiaceae, along with specific metabolites, were associated with CAR T-cell clinical outcomes. These multimodal profiles were integrated into response models, including one that identified patients likely to achieve a complete response by days 100 and 180 after infusion. These findings suggest that metabolites and gut microbiota correlate with CAR T-cell therapy responses and can be a valuable tool for risk assessment., This work has been partially supported by grants from the Instituto de Salud Carlos III (cofunded by the European Union), Spanish Ministry of Health (FIS PI18/00775, PICI18/00012 ICI19/00025, PI19/00669, PI22/00647, and complementary grant for CONCORD-023), Fondo Europeo de Desarrollo Regional “una manera de hacer Europa” 2021SGR01292 (AGAUR; Generalitat de Catalunya), “La Caixa” Foundation (CP042702/LCF/PR/GN18/50310007), RICORS-TERAV network (RD21/0017/0009 and RD21/0017/0019), Red de Terapia Celular (RD16/0011/0005), Centro de Investigación Biomédica en Red de Cáncer (CB16/12/00369 and CB16/12/00489), Asociación Española Contra el Cáncer (LABAE21971FERN), and Fundació Bosch I Aymerich., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Macrophage activation syndrome-like in multiple myeloma patients treated with the academic CAR-T against BCMA ARI0002h

  • Munárriz, Daniel
  • Rodríguez-Lobato, Luis Gerardo
  • López-Corral, Lucía
  • Arnaldos-Pérez, Cristina
  • Cabañas, Valentín
  • López-Muñoz, Nieves
  • Oliver-Caldés, Aina
  • Ponce, Juan Carlos
  • Reguera, Juan Luis
  • Martín, Ana-África
  • Martínez-Cibrián, Nuria
  • Tovar, Natalia
  • Delgado, Julio
  • Guillén, Elena
  • Varea, Sara
  • Rodríguez-Otero, Paula
  • Urbano-Ispizúa, Álvaro
  • Moraleda, José María
  • Martínez-López, Joaquín
  • Mateos, Maria Victoria
  • González-Calle, Verónica
  • González-Navarro, Europa Azucena
  • Fernández de Larrea, Carlos
[Background:] Chimeric antigen receptor T-cell (CAR-T) therapy targeting B-cell maturation antigen (BCMA) has revolutionized multiple myeloma treatment (MM). However, managing its immune-mediated adverse events, particularly macrophage activation syndrome-like (MAS-like), remains challenging due to underreporting., [Methods:] This multicentre, retrospective, analytical study evaluated MM patients treated with the anti-BCMA academic product ARI0002h. MAS-like was defined using the University of California San Francisco (UCSF) consensus criteria. Primary endpoints included baseline characteristics, predictive factors, and survival outcomes associated with MAS-like., [Results:] Of 80 patients, 12 (15%) met the UCSF criteria for MAS-like. These patients presented higher ISS scores (ISS III: 54.5% vs. 15.2%; p = 0.006), elevated serum monoclonal components (31.3 g/L vs. 6.8 g/L; p = 0.004), and a higher prevalence of extramedullary disease (41.7% vs. 16.2%; p = 0.057). MAS-like typically emerged 9 days post-infusion, with elevated ferritin, followed by LDH (median 11.5 days) and hypofibrinogenemia (median 14 days). One-third of patients met all UCSF criteria, and all exhibited hypertriglyceridemia, hypertransaminasemia, and cytopenias. Histopathological examination was positive in 63% of evaluated patients. Patients who developed MAS-like had poorer responses (CR: 25% vs. 68%; p = 0.008) and shorter median PFS and OS (7 months vs. 21.4 months and 18 months vs. not reached, respectively; p = 0.004). Those meeting all UCSF criteria had even inferior outcomes., [Conclusions:] MAS-like is associated with poorer responses, reduced PFS and OS, especially in patients meeting all UCSF criteria. High tumour burden, including elevated monoclonal component, high ISS and extramedullary disease, seems to contribute to MAS-like development., The author(s) declare financial support was received for the research and/or publication of this article. This study was supported by grants from the Instituto de Salud Carlos III (cofounded by the European Union) and the Spanish Ministry of Health (ICI19/00025 and PI22/00647), the RICORS-TERAV network (RD21/0017/0009 and RD21/0017/0019, RD21/0017/0001, RD21/0017/0006 and RD21/0017/0030), Red de Terapia Celular TERCEL (RD16/0011/0005), Fondo Europeo de Desarrollo Regional, 2021-SGR-01292 (AGAUR; Generalitat de Catalunya), Centro de Investigación Biomédica en Red de Cáncer (CB16/12/00369 and CB16/12/00489), La Caixa Foundation (CP042702/LCF/PR/GN18/50310007), Asociación Española Contra el Cancer LABAE21971FERN, and Fundació Bosch I Aymerich support. AO-C. from the resident grant Ajut Clínic-La Pedrera 2019, granted by Hospital Clínic de Barcelona. LR-L. has received funding from the CRIS Cancer Foundation (project number: PR_TMT_2023-6)., Peer reviewed